Medtronic PLC (MDT) to Issue Quarterly Dividend of $0.71 on April 17th

Medtronic PLC (NYSE:MDT) declared a quarterly dividend on Thursday, March 5th. Stockholders of record on Friday, March 27th will be paid a dividend of 0.71 per share by the medical technology company on Friday, April 17th. This represents a c) annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th.

Medtronic has raised its dividend payment by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 49 years. Medtronic has a dividend payout ratio of 47.2% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Medtronic to earn $5.83 per share next year, which means the company should continue to be able to cover its $2.84 annual dividend with an expected future payout ratio of 48.7%.

Medtronic Stock Down 0.7%

Medtronic stock opened at $86.56 on Wednesday. The company has a market capitalization of $111.13 billion, a PE ratio of 24.11, a price-to-earnings-growth ratio of 2.24 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The firm has a 50 day moving average price of $96.43 and a 200 day moving average price of $96.64.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. During the same period in the prior year, the firm earned $1.38 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts expect that Medtronic will post 5.46 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on MDT shares. Wall Street Zen lowered Medtronic from a “buy” rating to a “hold” rating in a research note on Sunday, March 1st. UBS Group reiterated a “neutral” rating and set a $104.00 price target on shares of Medtronic in a research note on Wednesday, February 4th. CICC Research initiated coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “outperform” rating on the stock. Mizuho raised shares of Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. Finally, Citigroup initiated coverage on shares of Medtronic in a report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).